Loading...
•
Sep 30, 2022
Agenus Q3 2022 Earnings Report
Agenus reported financial results for the third quarter of 2022.
Key Takeaways
Agenus reported revenue of $22.8 million and a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022. The company ended the quarter with $218.2 million in cash, cash equivalents, and short-term investments.
Botensilimab demonstrated impressive clinical responses in nine cold, treatment-resistant tumor types with strong durability.
Phase 2 ACTIVATE trials were initiated in advanced MSS colorectal cancer and melanoma.
Expanded clinical and regulatory leadership team to accelerate botensilimab development.
Continued to advance clinical pipeline through company-led studies and corporate partnerships.
Forward Guidance
Agenus is focused on expanding the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies, and adjuvants.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...